ArticleNeuro-oncology2005
Modeling prognosis for patients with malignant astrocytic gliomas: quantifying the expression of multiple genetic markers and clinical variables.
Article in Neuro-oncology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 53 citations in OpenAlex.
- The cuproptosis-related signature associated with the tumor environment and prognosis of patients with glioma.Frontiers in immunology · 2022Article
- RPS9 promotes the progression of NSCLC via activation Stat3 and Erk signaling pathways.Journal of Cancer · 2022Article
- Tectorigenin Inhibits Glioblastoma Proliferation by G0/G1 Cell Cycle Arrest.Medicina (Kaunas, Lithuania) · 2020Article
- Identification of Immune-Related Genes Contributing to the Development of Glioblastoma Using Weighted Gene Co-expression Network Analysis.Frontiers in immunology · 2020Article
- Overexpression of EPAC2 reduces the invasion of glioma cells via MMP-2.Oncology letters · 2019Article
- MiR-338-5p Promotes Glioma Cell Invasion by Regulating TSHZ3 and MMP2.Cellular and molecular neurobiology · 2018Article
- Identification of breast cancer hub genes and analysis of prognostic values using integrated bioinformatics analysis.Cancer biomarkers : section A of Disease markers · 2017Article
- The role of EGFR double minutes in modulating the response of malignant gliomas to radiotherapy.Oncotarget · 2017Article
- Down-regulation of RPS9 Inhibits Osteosarcoma Cell Growth through Inactivation of MAPK Signaling Pathway.Journal of Cancer · 2017Article
- Article
- A pilot study of bevacizumab-based therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas.Journal of neuro-oncology · 2016Article
- Chronic inflammation: is it the driver or is it paving the road for malignant transformation?Genes & cancer · 2015Article
- Validation of housekeeping genes for gene expression analysis in glioblastoma using quantitative real-time polymerase chain reaction.Brain tumor research and treatment · 2015Article
- Overexpression of vascular endothelial growth factor indicates poor outcomes of glioma: a systematic review and meta-analysis.International journal of clinical and experimental medicine · 2015Article
- IGF-Binding Protein 2 - Oncogene or Tumor Suppressor?Frontiers in endocrinology · 2015Review
- Vitamin D receptor expression is associated with improved overall survival in human glioblastoma multiforme.Journal of neuro-oncology · 2014Article
- Plasma IGFBP-2 levels after postoperative combined radiotherapy and chemotherapy predict prognosis in elderly glioblastoma patients.PloS one · 2014Article
- Identification of mutated core cancer modules by integrating somatic mutation, copy number variation, and gene expression data.BMC systems biology · 2013Article
- Imaging biomarkers of angiogenesis and the microvascular environment in cerebral tumours.The British journal of radiology · 2011Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The disparate lengths of survival among patients with malignant astrocytic gliomas (anaplastic astrocytomas [AAs] and glioblastoma multiforme [GBM]) cannot be adequately accounted for by clinical variables (patient age, histology, and recurrent status). Using real-time quantitative reverse transcription-polymerase chain reaction, we quantified the expression of four genes that were putative prognostic markers (CDK4, IGFBP2, MMP2, and RPS9) in a set of 43 AAs, 41 GBMs, and seven adjacent normal brain tissues. We previously explicated the expression and prognostic value of PAX6, PTEN, VEGF, and EGFR in these glioma tissues and established a comprehensive prognostic model (Zhou et al., 2003). This study attempts to improve that model by including four additional genetic markers, which exhibited a differential expression (P < 0.001) among tumor grades and between tumor and normal tissues. By including eight log-scaled gene expression variables, three clinical variables, and interaction terms among the eight genes, we established a prognostic model that accounted for two thirds of the variation (R2) in survival for this set of patients. To improve the R2 of the model without compromising its clinical utility, our data demonstrated that incorporating genes from different pathways markedly strengthens the model. Spearman rank correlation analysis of gene expression demonstrated a statistically significant positive correlation (P < 0.01) between the expression of IGFBP2-MMP2 and IGFBP2-VEGF in GBMs, but not in AAs. This finding suggests that the expression of IGFBP2 is associated with pathways activated specifically in GBMs that result in enhancing invasiveness and angiogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.